OBJECTIVE: The goal of this study was to pilot a randomized controlled trial of OROS methylphenidate (OROS-MPH) to treat attention deficit hyperactivity disorder (ADHD) plus epilepsy. METHODS:Thirty-three patients, 6-18years of age, taking antiepileptic drugs and with a last seizure 1-60months prior were assigned to a maximum daily dose of 18, 36, or 54mg of OROS-MPH in a double-blind placebo-controlled crossover trial. RESULTS: There were no serious adverse events and no carryover effects in the crossover trial. OROS-MPH reduced ADHD symptoms more than did placebo treatment. There were too few seizures during the active (5) and placebo arms (3) to confidently assess seizure risk; however, considering exposure time, we observed an increased daily risk of seizures with increasing dose of OROS-MPH, suggesting that potential safety concerns require further study. CONCLUSION: A larger study to assess the effect of OROS-MPH on seizure risk is needed. A crossover design including subjects with frequent seizures could maximize power and address high patient heterogeneity and recruitment difficulties. Copyright 2010 Elsevier Inc. All rights reserved.
RCT Entities:
OBJECTIVE: The goal of this study was to pilot a randomized controlled trial of OROS methylphenidate (OROS-MPH) to treat attention deficit hyperactivity disorder (ADHD) plus epilepsy. METHODS: Thirty-three patients, 6-18years of age, taking antiepileptic drugs and with a last seizure 1-60months prior were assigned to a maximum daily dose of 18, 36, or 54mg of OROS-MPH in a double-blind placebo-controlled crossover trial. RESULTS: There were no serious adverse events and no carryover effects in the crossover trial. OROS-MPH reduced ADHD symptoms more than did placebo treatment. There were too few seizures during the active (5) and placebo arms (3) to confidently assess seizure risk; however, considering exposure time, we observed an increased daily risk of seizures with increasing dose of OROS-MPH, suggesting that potential safety concerns require further study. CONCLUSION: A larger study to assess the effect of OROS-MPH on seizure risk is needed. A crossover design including subjects with frequent seizures could maximize power and address high patient heterogeneity and recruitment difficulties. Copyright 2010 Elsevier Inc. All rights reserved.
Authors: J Kaufman; B Birmaher; D Brent; U Rao; C Flynn; P Moreci; D Williamson; N Ryan Journal: J Am Acad Child Adolesc Psychiatry Date: 1997-07 Impact factor: 8.829
Authors: Joseph Gonzalez-Heydrich; Hesham M Hamoda; Laura Luna; Sneha Rao; James McClendon; Peter Rotella; Deborah Waber; Katherine Boyer; Steven V Faraone; Jane Whitney; Danielle Guild; Joseph Biederman Journal: Neuropsychiatry (London) Date: 2012-10-01
Authors: Isabell Brikell; Qi Chen; Ralf Kuja-Halkola; Brian M D'Onofrio; Kelsey K Wiggs; Paul Lichtenstein; Catarina Almqvist; Patrick D Quinn; Zheng Chang; Henrik Larsson Journal: Epilepsia Date: 2019-01-25 Impact factor: 5.864
Authors: Mesha-Gay Brown; Danielle A Becker; John R Pollard; Christopher Todd Anderson Journal: Curr Neurol Neurosci Rep Date: 2013-06 Impact factor: 5.081
Authors: Xinyue Liu; Paul R Carney; Regina Bussing; Richard Segal; Linda B Cottler; Almut G Winterstein Journal: J Child Adolesc Psychopharmacol Date: 2017-10-13 Impact factor: 2.576
Authors: Kelsey K Wiggs; Zheng Chang; Patrick D Quinn; Kwan Hur; Robert Gibbons; David Dunn; Isabell Brikell; Henrik Larsson; Brian M D'Onofrio Journal: Neurology Date: 2018-02-23 Impact factor: 9.910